TBMC will leverage existing resources to integrate intelligent and smart platform to establish various biopharmaceuticals manufacturing facility.

ImmunAdd develops innovative and practical solutions for human health. We aim to harness the immune system to create next-generation immunotherapeutics for the treatment of infectious diseases and cancer. Our next-generation adjuvants provide better immune activities in combination with anti-infection and anti-cancer vaccines. ImmunAdd has developed an efficient and sustainable manufacturing process for IA-05. With POC purpose, ImmunAdd will continue to expand our development to clinical-stage programs.

Neurology
Pipeline
Utilizing Yoda’s proprietary AI-based drug screening platform, we engage in the exploration and development of promising and beneficial products to address unmet medical needs, instilling new hope in patients.YA-101 Multiple System Atrophy
YA-102 Parkinson's Disease
YA-201 Alzheimer's Disease
Neuropsychiatry
YA-301
Schizophrenia
YA-401 Autism
Cerebrovascular Disease
YA-501 Ischemic Stroke
YA-502
Traumatic Brain Injury